IL17A and neoplasm: Besides, IL-17 acts on stromal cells to induce various angiogenic factors involved in tumor angiogenesis, as well as to induce the mobilization and recruitment of immature bone myeloid cells resulting in reduced efficacy of anti-angiogenic therapy (138, 139).